---

Published: 12 June 2017

1. Exclusive licensing agreement with Eli Lilly enables Lupin to commercialize and distribute Cialis©
2. Jubilant Life to buy Triad Isotopes' radio-pharmacy business
3. SkinCeuticals announces partnership with ReSurge International
4. AstraZeneca has paid $45 million and committed to up to $2.1 billion in milestones to team with Pieris Pharmaceuticals
5. Sosei pays £35M stake, with future buyout option, for British biotech MiNA
6. LivaNova buys Caisson Interventional, a Minnesota-based heart valve maker, for $72 million.
7. Sanofi inks €250M bispecific small molecule diabetes deal
8. Takeda pens GammaDelta Therapeutics $100M pact, with M&A option
9. Prolific dealmakers Akebia and Vifor pen anemia drug pact
10. Bioverativ to buy True North for $400M upfront
11. Heptares nabs $5M from Teva for new migraine molecule
12. OSE Immunotherapeutics inks $10.7M deal with Servier to develop and commercialize its interleukin-7 antagonist targeting autoimmune disease

For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.

Updates at Aagami:

1. New Client Win: Outreach and Business Development for a high growth US Med Tech company which has a promise to impact billions
2. New Client Win: Outlicensing of Korean client's Anti-Retinal-Disease and Anti-cancer Drugs
3. New Client Win - Partnering support to a US based bio-targeted nanomedicines company with world-wide exclusive rights to a novel and innovative drug-targeting platform technology
4. Aagami to attend BIO International Convention, 40+ meetings already scheduled with pre-defined agenda.